Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

13 Mar 2017

• By Joseph Haas and Lucie Ellis-Taitt

DealWatch_1200x675

Related Content

Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

25 Sep 2014

The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin

07 Mar 2017

WHO Publishes List Of Pathogen Threats To Rouse Drug Developers

01 Mar 2017

Merck's Biosims Business: What's For Sale And Who Will Buy It?

10 Mar 2017

Vertex Plays Defense In CF With Concert Deal

06 Mar 2017

Allergan Exits <em>Noctiva</em> Partnership With Serenity Just As FDA Approves Controversial Drug

07 Mar 2017

Solithera’s Prospects Look Grim Following Complete Response Letter

30 Dec 2016

Related Companies

Melinta Therapeutics, Inc.

Seelos Therapeutics, Inc.

Ferring Pharmaceuticals

Scorpius Holdings, Inc.

Sanofi

MedImmune LLC

AstraZeneca PLC

AIMM Therapeutics B.V.

Cadent Therapeutics

Cadent Therapeutics

Saniona AB

Biogen, Inc.

Novartis AG

Les Laboratoires Servier

Ligand Pharmaceuticals, Inc.

Theratechnologies Inc.

TaiMed Biologics, Inc.

Merck KGaA

Vertex Pharmaceuticals Incorporated

Serenity Pharmaceuticals LLC

Allergan plc

Concert Pharmaceuticals, Inc.

Additional Topics

Deals M & A Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.